Novo Nordisk A/S

Eli Lilly and Company

Innovent Biologics is the first company in China to mount a real challenge to pharmaceutical giants Novo Nordisk and Eli Lilly in the obesity market. The approval of its weight loss drug opens a new chapter in the rapidly growing Chinese market, where local manufacturers are seeking to squeeze out foreign leaders with their expensive GLP-1 injections. What will the increased competition lead to and should the makers of Ozempic and Mounjaro be wary of the Chinese threat?

China approves Ozempic's first domestic competitor. What do investors need to know?

AstraZeneca PLC

At least a dozen companies are looking for a way to reduce muscle mass loss when taking weight loss drugs

Eli Lilly is entering a market valued at $30 billion, can it beat the competition?

JPMorgan Chase & Co.

Reddit, Inc.

Daily review and forecast of events on the US stock market from&nbsp;Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: investors focus on US Fed decisions

Verve Therapeutics, Inc.

Shares of startup Verve soared more than 75% after the acquisition announcement


Eli Lilly will buy a genetic engineering startup. What signal does this send to investors?

Amazon.com, Inc.

First Solar, Inc.

Morning in New York: Middle East conflict increases uncertainty

Danish drugmaker Novo Nordisk seeks new chief executive after share price slump

An activist investor has taken an interest in the manufacturer Ozempic. What is it known for?  

Tesla, Inc.

Rheinmetall AG

Musk had a fight with Trump: what it means for investors. Nvidia briefly regained the title of the world's most valuable company. Alphabet threatens to drop in value by a quarter. The defense company will enter the eurozone's largest index. Read about the main news from June 2 to June 6 in our review.&nbsp;

Highlights of the week: Musk and Trump spat, Nvidia gave back $1 trillion, tanks instead of Gucci

Shares of ProMIS Neurosciences, which makes drugs for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS), <a href="https://www.nasdaq.com/market-activity/stocks/pmn?utm_source=in_materials">gained</a> more than 5% on Wednesday, October 30. This came after the company <a href="https://www.promisneurosciences.com/news-media/press-releases/detail/232/promis-neurosciences-presents-positive-data-from-pmn310?utm_source=in_materials">released</a> positive data from the earliest stage of clinical trials for its Alzheimer’s treatment. Currently, only two treatments are FDA-approved for Alzheimer’s: one jointly developed by Biogen and Eisai, and Eli Lilly’s drug.

Alzheimer’s drugmaker ProMIS gains on positive early trial data

"In my entire life, I never dreamed that we would be talking about medicines that are providing hope for people like me who have struggled for years with being overweight or with obesity," famous TV host <strong>Oprah Winfrey</strong> <a href="https://people.com/celebrities-ozempic-wegovy-what-theyve-said-7104926">told</a>  magazine two and a half years after Novo Nordisk's weight-loss drug Wegovy hit the market. Currently, Wegovy and Zepbound, made by U.S.-based Eli Lilly, account for 95% of the obesity market. In the upcoming years, however, they may face over a dozen new competitors. Which companies should investors keep an eye on in the space?

The skinny on investing in the weight-loss drug market

Shares of Lexaria Bioscience, a company that transforms the delivery of other companies’ drugs using its patented technology, <a href="https://www.nasdaq.com/market-activity/stocks/lexx">fell</a> more than 6% on Tuesday, October 15, after it <a href="https://ir.lexariabioscience.com/news-events/press-releases/detail/271/lexaria-announces-5-million-registered-direct-offering">announced</a> a raise of around $5 million through a private placement.

#: 10